Sichuan Qianli Beiyikang Medical Technology Co., Ltd. is a high-tech enterprise specializing in the R&D, production and sales of medical devices. The company's main products include medical dressings, medical adhesives, medical sutures, etc. The company has passed ISO13485 quality management system certification and EU CE certification.
This is a supplemental legal opinion (II) issued in September 2022 by Beijing Zhong Lun Law Firm for Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It supplements the earlier legal opinion, lawyer's work report and supplemental legal opinion (I) prepared for the company's public offering of shares to non-specific qualified investors and listing on the Beijing Stock Exchange, and covers changes in legal matters from January 1, 2022 to June 30, 2022, the supplementary reporting period.
The document updates matters related to the offering and listing, including approvals and authorizations, the issuer's subject qualification, the substantive conditions for the offering, the issuer's property, tax, labor and social security matters, use of raised funds and litigation, and updates responses to questions in the review inquiry letter. It also includes nine appendices covering new domestic and foreign patents, trademarks, branches, leased premises, ongoing litigation, inspection reports and product quality liability arrangements with major customers and suppliers. This manual is written in Chinese.
The board resolution of September 20, 2022 adjusted the issue price floor from 45 yuan per share to 31.8 yuan per share, with the other terms of the offering unchanged.
It covers legal matters of the issuer from January 1, 2022 to June 30, 2022, the supplementary reporting period, following the audit extended to June 30, 2022.
Yes; as of the date of this supplemental legal opinion the issuer remains a legally established and validly existing joint stock company and an innovation-tier listed company on the National Equities Exchange and Quotations for at least twelve consecutive months.
The resolution adjusting the listing plan still needs approval by the issuer's shareholders' meeting, and the offering and listing still need to pass Beijing Stock Exchange review and obtain registration consent from the China Securities Regulatory Commission.